

RESEARCH

Open Access

# NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors

N Daniel Berger<sup>1</sup>, Vinicius M Gadotti<sup>1</sup>, Ravil R Petrov<sup>2</sup>, Kevin Chapman<sup>1</sup>, Philippe Diaz<sup>2</sup> and Gerald W Zamponi<sup>1\*</sup>

## Abstract

**Background:** T-type calcium channels and cannabinoid receptors are known to play important roles in chronic pain, making them attractive therapeutic targets. We recently reported on the design, synthesis and analgesic properties of a novel T-type channel inhibitor (NMP-7), which also shows mixed agonist activity on CB<sub>1</sub> and CB<sub>2</sub> receptors *in vitro*. Here, we analyzed the analgesic effect of systemically delivered NMP-7 (intraperitoneal (i.p.) or intragastric (i.g.) routes) on mechanical hypersensitivity in inflammatory pain induced by Complete Freund's Adjuvant (CFA) and neuropathic pain induced by sciatic nerve injury.

**Results:** NMP-7 delivered by either i.p. or i.g. routes produced dose-dependent inhibition of mechanical hyperalgesia in mouse models of inflammatory and neuropathic pain, without altering spontaneous locomotor activity in the open-field test at the highest active dose. Neither i.p. nor i.g. treatment reduced peripheral inflammation *per se*, as evaluated by examining paw edema and myeloperoxidase activity. The antinociception produced by NMP-7 in the CFA test was completely abolished in Ca<sub>v</sub>3.2-null mice, confirming Ca<sub>v</sub>3.2 as a key target. The analgesic action of intraperitoneally delivered NMP-7 was not affected by pretreatment of mice with the CB<sub>1</sub> antagonist AM281, but was significantly attenuated by pretreatment with the CB<sub>2</sub> antagonist AM630, suggesting that CB<sub>2</sub> receptors, but not CB<sub>1</sub> receptors are involved in the action of NMP-7 *in vivo*.

**Conclusions:** Overall, our work shows that NMP-7 mediates a significant analgesic effect in a model of persistent inflammatory and chronic neuropathic pain by way of T-type channel modulation and CB<sub>2</sub> receptor activation. Thus, this study provides a novel therapeutic avenue for managing chronic pain conditions *via* mixed CB ligands/T-type channel blockers.

**Keywords:** T-type calcium channels, Neuropathic pain, Inflammatory pain, Cannabinoid receptors, Analgesia

## Background

Pathological chronic pain results from peripheral and central alterations in the nociceptive pathway. This persistent pain is difficult to treat and has a negative impact on a patient's quality of life, as well as economic impacts associated with loss of productivity and cost of treatment. Chronic inflammatory and chronic neuropathic pain results from tissue injury and nerve injury, respectively, and both involve a peripheral and central sensitization event that culminate in pain from normally innocuous stimuli, allodynia, or exacerbated pain from otherwise

mildly aversive stimuli, hyperalgesia [1]. The development of novel analgesics is paramount to the effective treatment of chronic pain, and the development of novel molecular entities targeting multiple mechanisms of pain neurobiology may be an attractive method to effectively mediate pain with lower compound doses, and reduced side effects [2].


Nociceptive transmission relies in part on low-voltage-activated T-type calcium channels that open in response to small membrane depolarizations [3]. T-type calcium channels are expressed along the primary afferent pain pathway [4-6] and these channels—in particular T-type channel subtype Ca<sub>v</sub>3.2—have shown potential as targets for analgesics [6]. Selective antisense oligonucleotide-mediated Ca<sub>v</sub>3.2

\* Correspondence: zamponi@ucalgary.ca

<sup>1</sup>Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada  
Full list of author information is available at the end of the article

knockdown [7,8] or inhibition of the T-type calcium channel by T-type channel modulators produce significant antinociceptive effects *in vivo* [9-13]. Painful diabetic neuropathies can be reversed by inhibiting T-type channels [14] as well as by  $Ca_v3.2$  antisense-mediated knockdown [15].  $Ca_v3.2$  knockout mouse strains also show attenuated pain responses in the formalin-induced pain model [16]. Importantly, our laboratory has recently shown that interfering with  $Ca_v3.2$  channel trafficking mediates analgesia in mouse models of inflammatory and neuropathic pain [17].

In addition to T-type calcium channels, the cannabinoid system has been recognized as a potential pharmacological target for chronic pain. The antinociceptive effects of the cannabinoid system make it an attractive target for relief of chronic pain, and randomized-controlled trials have indeed shown that cannabis use results in significant analgesia [18]. Interestingly, the endogenous cannabinoid anandamide also modulates T-type channels directly to produce thermal analgesia in a  $Ca_v3.2$ -dependent manner [19,20]. Additionally, both  $\Delta^9$ -THC and cannabidiol [21] or the endogenous cannabinoid anandamide and its derivatives [20-22] inhibit T-type channel activity. The use of such mixed CB/T-type calcium channel interacting compounds may provide a strategy for the development of better analgesics [23]. Indeed, combining different mechanisms of action in a single drug could possess several advantages that may include increased potency and effect duration, with a reduction of side effects and overall lower dose of the compound. In this context, we have previously reported that a series of mixed T-type channel inhibitors/cannabinoid receptor agonists, including NMP-7 (Figure 1), dose-dependently reduce



formalin-induced nociception in mice [24]. NMP-7 was determined *in vivo* to have potent T-type channel blocking activity in electrophysiological measurements, and a 10-fold higher preference for  $CB_2$  receptors over  $CB_1$  receptors [24]. Here, we report on the antinociceptive action of NMP-7 in a model of persistent inflammatory pain and chronic neuropathic pain in mice, and identify *in vivo* the underlying mechanism of action of this compound.

## Results


### Analgesic effect of NMP-7 in persistent inflammatory pain and chronic neuropathic pain

To determine whether NMP-7 mediates an antinociceptive effect in mouse models of persistent inflammatory pain, we analyzed mechanical hypersensitivity in CFA-injected animals after systemic treatment with NMP-7. As shown in Figure 2A, B, mice injected with CFA developed mechanical hyperalgesia as indicated by a decrease in paw withdrawal thresholds when compared to the pre-CFA baseline levels of the vehicle control group (Two-way ANOVA,  $p < 0.0001$ ). Three days after CFA injection, intraperitoneal treatment of mice with NMP-7 at 0.1 and 0.3 mg/kg significantly reversed mechanical hyperalgesia induced by CFA from 30 minutes up to 1 hour ( $p < 0.001$  for 0.3 mg/kg) relative to vehicle-treated controls (Figure 2A). Similarly, intragastric NMP-7 treatment at 3 and 10 mg/kg significantly reversed mechanical hyperalgesia from 30 minutes up to two hours after treatment ( $p < 0.01$  and  $p < 0.05$  respectively for 10 mg/kg) (Figure 2B). In contrast, treatment of mice with vehicle control (PBS +5% DMSO) had no effect on the mechanical hyperalgesia induced by CFA injection.

As seen in Figure 2C, partial sciatic nerve injury also produced significant mechanical hypersensitivity in mice when compared to sham-operated mice ( $p < 0.001$ ). Intraperitoneal administration of NMP-7 (0.3 mg/kg) significantly decreased mechanical hyperalgesia from 30 minutes to two hours post-treatment, with a maximum effect observed at one hour post-treatment (Two-way ANOVA) (Figure 2C). Neither intraperitoneal (Figure 3A) nor intragastric (Figure 3B) treatment of mice with NMP-7 significantly altered the number of crossings in the open field test with the active doses. Taken together, these data show NMP-7 mediates a significant antinociceptive effect against CFA-induced persistent inflammatory pain and neuropathic pain with no nonspecific sedative or ataxic effects.

### NMP-7 does not affect inflammation per se


To rule out the possibility that NMP-7 may directly affect CFA-induced persistent inflammation we analyzed the effects of NMP-7 on paw volume and MPO activity. CFA injection 3 days prior to measurement produced



significant paw edema (Two-way ANOVA,  $p < 0.0001$ ) and neutrophil infiltration (One-way ANOVA,  $p < 0.0001$ ) when compared to baseline measurements and PBS controls. Treatment of mice with NMP-7 at the active doses 0.3 mg/kg, i.p. (Figure 4A, C) or 10 mg/kg, i.g. (Figure 4B, D) yielded no significant decrease in peripheral myeloperoxidase levels (indicative of tissue neutrophil infiltration) 60 minutes post-treatment (Figure 4A, B), as well as no significant decrease in paw volume as assessed by plethysmometer (Figure 4C, D) relative to vehicle-treated control animals. These results show that NMP-7 does not mediate a direct peripheral anti-inflammatory effect.

#### The mechanism of NMP-7 action involves $Ca_v3.2$ T-type calcium channels

To investigate whether the  $Ca_v3.2$  T-type calcium channel subtype is involved in NMP-7-mediated antinociception, the analgesic effect of NMP-7 delivered systemically (i.p.) was investigated in a  $Ca_v3.2$  knockout mouse strain. In response to CFA, these mice showed similar mechanical withdrawal thresholds relative to wild-type mice (Figure 5), as previously reported [17]. This is presumably due to compensation from other ion channels (for example sodium channels, although this has not been experimentally validated). Treatment with NMP-7 at 0.3 mg/kg, i.p. three




**Figure 3** Effect of intraperitoneal (A) and intragastric (B) NMP-7 treatment in the open field test. Bars represent means  $\pm$  SEM of total number of crossings of 10–14 animals. Control values (black bars) represent vehicle-treated group (PBS +5% DMSO) (Student's *t*-test, ns = non-significant).


days post-CFA injection produced a significant inhibition of mechanical hyperalgesia in wild type mice as expected (Three-way ANOVA,  $p < 0.0001$ ), however  $Ca_v3.2$ -null mice showed complete insensitivity to NMP-7 treatment (Figure 5A, B). These data validate  $Ca_v3.2$  as a primary target in the mechanism of NMP-7 action *in vivo*.

**The mechanism of NMP-7 action involves  $CB_2$ , but not  $CB_1$  receptors**

To determine the extent of CB receptor involvement in NMP-7's mechanism of action *in vivo*, the selective  $CB_1$  antagonist AM281 and the  $CB_2$  antagonist AM630 were delivered to mice prior to NMP-7 treatment. Systemic



**Figure 4** Effect of intraperitoneal (A, C) or intragastric (B, D) treatment with NMP-7 on tissue myeloperoxidase (MPO) activity (Panel A and B) and paw volume (Panel C and D). Bars represent mean  $\pm$  SEM MPO units per mg of tissue (Panel A, B) and mean  $\pm$  SEM of paw volumes (Panel C, D) of 7–10 mice when NMP-7 was delivered i.p. and 4–5 mice when delivered i.g. ### $p < 0.001$  when compared to the non-inflamed group (20  $\mu$ l of PBS injected intraplantarly), ns = non significant relative to the inflamed vehicle-treated controls (PBS +5% DMSO).



pretreatment of mice with AM630 (3 mg/kg, i.p.) significantly attenuated the analgesic effects of NMP-7 (0.3 mg/kg, i.p.) at both 30 and 60 minutes post-treatment (Two-way ANOVA,  $p < 0.01$ ) (Figure 6A). AM630 also reversed the analgesic effect of URB597 (10 mg/kg, i.p., an inhibitor of fatty acid amide hydrolase, the primary degradatory enzyme for the endocannabinoid anandamide), which was used as positive control (Two-way ANOVA,  $p < 0.01$ ) (Figure 6A).


Systemic treatment of mice with the  $CB_1$  antagonist AM281 (0.5 mg/kg i.p.) did not reverse the antinociceptive action of NMP-7 (0.3 mg/kg, i.p.) at both 30 and 60 minutes post-treatment (Figure 6B). Yet, AM281 reversed the antinociceptive action of JZL184 (16 mg/kg, i.p., an irreversible inhibitor of monoacylglycerol lipase, the primary degradatory enzyme for endocannabinoid 2-arachidonoylglycerol) (Two-way ANOVA,  $p < 0.05$ ) (Figure 6B), thus confirming that AM281 was indeed active *in vivo*. These data suggest that  $CB_2$ , but not  $CB_1$  receptors are involved in the analgesic effect of NMP-7.

### Discussion

In this study, we have shown that the mixed CB agonist/T-type calcium channel inhibitor NMP-7 is efficacious in mediating analgesia in persistent inflammatory and chronic neuropathic pain through a mechanism that is dependent on  $Ca_v3.2$  calcium channels and  $CB_2$  receptors, but not  $CB_1$  receptors.

NMP-7 was previously characterized in an acute pain model in mice (i.e., injection of formalin into the hind paw) and was shown to attenuate both phases in a dose-dependent fashion when delivered intrathecally [24]. The effect in the second acute inflammatory phase of the formalin test suggested possible efficacy against persistent inflammatory pain. Indeed, as shown here, NMP-7 reversed the mechanical hyperalgesia in the CFA model of persistent inflammatory pain in a dose-dependent fashion for up to one hour when administered intraperitoneally, and two hours administered intragastrically. Furthermore, this compound reversed mechanical hyperalgesia following a peripheral nerve injury for up to two hours post-treatment. When administered systemically, NMP-7 resulted in significantly increased mechanical withdrawal thresholds without mediating non-specific sedative or ataxic effects at the active doses, as assessed by the open field test.

Systemic, peripheral and intrathecal administration of T-type calcium channel blockers such as mibefradil and ethosuximide have been previously shown to reverse mechanical and thermal hypersensitivity in response to nerve injury [11]. Inhibition of T-type channels or *in vivo* antisense-mediated knockdown produces antinociception in these and other models of chronic pain [7-16]. Conversely, increased T-type channel activity in the primary pain pathway occurs in models of chronic pain such as spinal nerve injury [25], peripheral nerve injury [26], colonic hypersensitivity [8] and diabetic neuropathy [27]. Altogether, these data indicate that T-type calcium channels mediate a pronociceptive role, and hence blockers that target these channels have the propensity to mediate analgesia. Along these lines, systemic and local administration of  $CB_2$  receptor agonists have been reported to



**Figure 6** Effect of pre-treatment of mice with selective CB<sub>2</sub> (A) and CB<sub>1</sub> (B) antagonists on the analgesic action of NMP-7. Each bar represents mean ± SEM responses of 5–9 mice. Asterisks denote significance relative to vehicle-treated controls (PBS +5% DMSO), \**p* < 0.05, \*\**p* < 0.01, \*\*\**p* < 0.001. #*p* < 0.05, ###*p* < 0.001 and ns = non significant when compared to antagonist-treated groups (Two-way ANOVA, followed by a Tukey's test).

produce analgesia in mice with peripheral nerve injuries, altogether indicating that both T-type calcium channels and CB<sub>2</sub> receptors are important targets for treating neuropathic pain [28]. Here we show that a single compound, NMP-7, can target both of these pathways to trigger analgesic effects in not only neuropathic pain, but also hypersensitivity in response to CFA injection. Our data show that NMP-7 mediates its antinociceptive action largely through modulation of T-type calcium channels, and in part by CB<sub>2</sub> receptor activation. Indeed, Ca<sub>v</sub>3.2-null mice were completely insensitive to the NMP-7 treatment and blocking CB<sub>2</sub> receptors with AM630 also mediated a significant (albeit incomplete) reduction in the

analgesic effects of this compound. This suggests that although NMP-7-mediated activation of CB<sub>2</sub> receptors mediates analgesia, this may require the presence of functional Ca<sub>v</sub>3.2 channels. One possible explanation could be that CB<sub>2</sub> receptors mediate their analgesic actions by inhibiting Ca<sub>v</sub>3.2 channels in afferent fibers. A number of second messenger pathways have indeed been shown to inhibit Ca<sub>v</sub>3.2 channel activity [3]. Hence, future studies should examine the possible coupling between CB<sub>2</sub> receptors and T-type calcium channels in both expression systems and in dorsal root ganglion neurons. NMP-7 also mediated an antihyperalgesic effect for different lengths of time when administered intraperitoneally

versus when administered intragastrically. This observed difference in the duration of NMP-7 effects is likely due to differential bioavailability of NMP-7; the pharmacokinetics of NMP-7 may differ between the two routes of administration.

CB<sub>1</sub> receptors are expressed throughout the brain and the spinal cord, where they modulate neurotransmitter release such as inhibition of glutamate release by spinal cord interneurons [29,30]. There is also evidence for CB<sub>1</sub> expression on nociceptors in the periphery [31]. However, CB<sub>1</sub> receptors almost exclusively mediate cannabis-related psychotropic effects, catalepsy and motor ataxia [29]. Hence, activation of CB<sub>2</sub> receptors for pain relief is preferable to CB<sub>1</sub> to avoid centrally-mediated psychotropic effects, and suppress the peripheral and central sensitization events that facilitate chronic pain development. NMP-7 fits this pharmacological profile as it binds to CB<sub>2</sub> receptors with higher affinity than CB<sub>1</sub> [24], and because of the inability of the CB<sub>1</sub> receptor antagonist AM281 to prevent NMP-7 action *in vivo*.

## Conclusions

Taken together, NMP-7 mediates a pronounced analgesic effect that is dependent on T-type Ca<sub>v</sub>3.2 channels and CB<sub>2</sub> receptors, and appears to cause no nonspecific motor effects at the therapeutic doses. Hence, T-type calcium channel blockers with CB<sub>2</sub> agonist activity such as NMP-7 may be a viable avenue for the development of new chronic pain drugs.

## Methods

### Drugs and reagents

NMP-7 was synthesized at the Core Laboratory for Neuromolecular Production at the University of Montana. NMP-7 was dissolved in DMSO (to a maximum of 5%) and PBS. Selective CB<sub>1</sub> antagonist AM281, irreversible inhibitor of monoacylglycerol lipase JZL184 [32,33], selective CB<sub>2</sub> antagonist AM630, and the irreversible inhibitor of fatty acid amide hydrolase URB597 [34] were provided by Cayman Chemical, and dissolved in phosphate buffered saline (PBS) and dimethyl sulfoxide (DMSO) to 5%. Complete Freund's Adjuvant (CFA), *o*-Dianisidine and DMSO were supplied by Sigma Aldrich. The myeloperoxidase (MPO) assay standard was supplied by Calbiochem (EMD Millipore).

### Animals and drug treatment

Experiments were conducted in accordance with a protocol approved by the University of Calgary's Institutional Animal Care and Use Committee, and all efforts were made to minimize animal suffering according to the policies and recommendations of the International Association for the Study of Pain. Adult male C57BL/6 J (wild-type) or *CACNA1H* knockout (Ca<sub>v</sub>3.2 null) mice (20–25 g, 6–8 weeks) were used and purchased from

the Jackson Laboratory. Animals were housed at a maximum of five per cage (30 × 20 × 15 cm) with *ad libitum* access to food and water. Animals were kept in controlled temperature of 23 ± 1°C on a 12 h light/dark cycles (lights on at 7:00 a.m.). When drugs were delivered by intraperitoneal (i.p.) and intragastric (i.g.) routes, a constant volume of 10 ml/kg body weight was injected. Appropriate vehicle-treated groups were also assessed simultaneously. All compounds, including NMP-7, were dissolved in DMSO to a maximum 5% concentration, and PBS. Control animals received PBS +5% DMSO, and sham animals received no drug or vehicle. Choices of drug doses were based on previous literature [35] and from pilot experiments.

### CFA-induced persistent inflammatory pain

To induce inflammatory chronic pain and paw swelling, mice received a 20-μl injection of CFA subcutaneously in the plantar surface of the right hindpaw (intraplantarily, i.pl.). Control groups received 20 μl of PBS in the right hindpaw. This CFA treatment produces significant paw inflammation with accompanying hyperalgesia. Animals received NMP-7 either intraperitoneally (0.03 to 0.3 mg/kg) or intragastrically (1 to 10 mg/kg) 3 days post-CFA injection.

### Neuropathic pain induced by sciatic nerve injury

To induce chronic neuropathic pain, mouse sciatic nerves were ligated according to Malmberg and Basbaum [36]. Briefly, mice were anesthetized under 4% isoflurane, and held at 2.5% for the remainder of the surgery. The sciatic nerve was exposed, and the distal one-third to one-half section of the dorsal side of the nerve was transected and tightly tied with silk sutures. Sciatic nerves were exposed in sham-operated mice, but not tied. NMP-7 was administered intraperitoneally (0.3 mg/kg) two weeks post-surgery prior to testing mechanical withdrawal thresholds. Investigators were blind to treatment conditions when measurements were performed.

### Measurement of mechanical hyperalgesia

For both the inflammatory and neuropathic pain models, mechanical hyperalgesia was measured using the Dynamic Plantar Aesthesiometer (Ugo Basile, Varese, Italy). Animals were placed individually in a small, enclosed testing arena (20 cm × 18.5 cm × 13 cm, length × width × height) on top of a wire mesh grid. Mice were allowed to acclimate for a period of at least 90 minutes. The aesthesiometer device was positioned beneath the animal such that the filament was directly under the plantar surface of the ipsilateral hind paw. Each paw was tested three to four times per session, and measurements taken before the injuries were considered baseline measurements (B). Mice that had not

developed persistent inflammatory or chronic neuropathic pain were excluded prior to treatment.

### Peripheral inflammation assays

In a different set of experiments from those described in the preceding section, peripheral inflammation was induced by a 20- $\mu$ l injection of CFA subcutaneously in the plantar surface of the right hindpaw (i.pl.). Control groups received 20  $\mu$ l of PBS in the right hindpaw. Mice received NMP-7 systemically (0.3 mg/kg, i.p. or 10 mg/kg, i.g.) 3 days post-CFA treatment, and paw volume was determined 60 minutes post-treatment by plethysmometer.

For the MPO assay, CFA- or PBS-treated back right hindpaws were collected 1 hour after NMP-7 administration at 0.3 mg/kg i.p. or 10 mg/kg i.g. Paws were homogenized with EDTA/NaCl buffer (pH 7.4), centrifuged at 4400 g (15 mins, 4°C), and the pellet was resuspended in ammonium bromide buffer (pH 5.4). The pellets were frozen and thawed three times in liquid nitrogen, and after the final thaw, re-centrifuged at 4400 g (15 mins, 4°C). 25  $\mu$ l of the supernatant was assessed for MPO activity by absorbance at 650 nm, with o-Dianisidine and 0.3 mM H<sub>2</sub>O<sub>2</sub> against an MPO standard.

### Open field test

Mouse ambulatory behavior was assessed in an open-field test as described previously [23]. The apparatus consisted of a wooden box measuring 40 × 60 × 50 cm with a frontal glass wall. The floor of the arena was divided into 12 equal squares and placed in a sound free room. Animals were placed in the rear left square and left to explore freely for 6 minutes, during which time the number of gridlines crossed with all paws (crossing) was counted. The apparatus was cleaned with a 70% alcohol solution and dried after each individual mouse session.

### Analysis of mechanism of action

To address the role played by T-type channels in the mechanisms by which NMP-7 produces antinociception, we tested NMP-7 delivered systemically at the active dose of 0.3 mg/kg in Ca<sub>v</sub>3.2 null mice in the CFA test. To investigate the involvement of CB<sub>1</sub> receptor activation, the CB<sub>1</sub> antagonist AM281 was administered alone and with NMP-7. JZL184 was used as a positive control, and was administered 15 minutes post-AM281 treatment in the same way as NMP-7. To investigate the extent of CB<sub>2</sub> receptor involvement, the CB<sub>2</sub> antagonist AM630 was delivered 15 minutes prior to NMP-7 treatment or URB597 treatment, which was used as a positive control.

### Data analysis

Each column or individual point (for line graphics) represents the mean ± SEM and is representative of at least 3 independent experimental runs. Data were evaluated

by One-way, Two-way or Three-way analysis of variance (ANOVA) followed by the Tukey's test, or alternatively a two-sample Student's *t*-test. A value of *p* < 0.05 was considered to be significant.

### Abbreviations

CFA: Complete Freund's Adjuvant; i.p.: Intraperitoneal; i.g.: Intragastric; CB: Cannabinoid.

### Competing interests

The authors declare that they have no competing interests.

### Authors' contributions

N.D.B., V.G.M., R.R.P., P.D. and G.W.Z. designed experiments. N.D.B., V.G.M. and K.C. performed experiments and analyzed data. G.W.Z. supervised the study, N.D.B. wrote the manuscript, and all authors read and approved the final manuscript.

### Acknowledgements

This work was supported by an operating grant to GWZ from the Canadian Institutes of Health Research and by National Institutes of Health (NIH) grant P30-NS055022 to PD and RRP. GWZ is a Canada Research Chair. NDB was supported by an Alberta Innovates—Health Solutions (AI-HS) Summer Studentship award and a Markin Undergraduate Student Research Program in Health & Wellness Award. VMG was supported by Fellowships from Mitacs, AI-HS and the Canadian Diabetes Association.

### Author details

<sup>1</sup>Department of Physiology and Pharmacology, Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Canada. <sup>2</sup>Core Laboratory for Neuromolecular Production, University of Montana, Missoula, MT, USA.

Received: 9 October 2014 Accepted: 2 December 2014

Published: 6 December 2014

### References

1. Basbaum AI, Bautista DM, Scherrer G, Julius D: Cellular and molecular mechanisms of pain. *Cell* 2009, **139**:267–284.
2. Horvath G, Kekesi G, Tuboly G, Benedek G: Antinociceptive interactions of triple and quadruple combinations of endogenous ligands at the spinal level. *Brain Res* 2007, **1155**:42–48.
3. Iftinca MC, Zamponi GW: Regulation of neuronal T-type calcium channels. *Trends Pharmacol Sci* 2009, **30**:32–40.
4. Hildebrand ME, Snutch TP: Contributions of T-type calcium channels to the pathophysiology of pain signaling. *Drug Discov Today Dis Mech* 2006, **3**:335–341.
5. Waxman SG, Zamponi GW: Regulating excitability of peripheral afferents: emerging ion channel targets. *Nat Neurosci* 2014, **17**:153–163.
6. Bourinet E, Altier C, Hildebrand ME, Trang T, Salter MW, Zamponi GW: Calcium-permeable ion channels in pain signaling. *Physiol Rev* 2014, **94**:81–140.
7. Bourinet E, Alloui A, Monteil A, Barrère C, Couette B, Poirot O, McRory J, Snutch TP, Eschalièr A, Nargeot J: Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. *EMBO J* 2005, **24**:315–324.
8. Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrère C, Pizzoccaro A, Muller E, Nargeot J, Snutch TP, Eschalièr A, Bourinet E, Ardid D: T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. *Proc Natl Acad Sci U S A* 2011, **108**:11268–11273.
9. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V: Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. *Brain Res* 2002, **951**:336–340.
10. Cheng JK, Lin CS, Chen CC, Yang JR, Chiou LC: Effects of intrathecal injection of T-type calcium channel blockers in the rat formalin test. *Behav Pharmacol* 2007, **18**:1–8.
11. Dogrul A, Gardell LR, Ossipov MH, Tulunay FC, Lai J, Porreca F: Reversal of experimental neuropathic pain by T-type calcium channel blockers. *Pain* 2003, **105**:159–168.



12. Flatters SJ, Bennett GJ: Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. *Pain* 2004, **109**:150–161.
13. Munro G, Erichsen HK, Mirza NR: Pharmacological comparison of anticonvulsant drugs in animal models of persistent pain and anxiety. *Neuropharmacology* 2007, **53**:609–618.
14. Latham JR, Pathirathna S, Jagodic MM, Choe WJ, Levin ME, Nelson MT, Lee WY, Krishnan K, Covey DF, Todorovic SM, Jevtovic-Todorovic V: Selective T-type calcium channel blockade alleviates hyperalgesia in ob/ob mice. *Diabetes* 2009, **58**:2656–2665.
15. Messinger RB, Naik AK, Jagodic MM, Nelson MT, Lee WY, Choe WJ, Orestes P, Latham JR, Todorovic SM, Jevtovic-Todorovic V: In vivo silencing of the Cav3.2 T-type calcium channels in sensory neurons alleviates hyperalgesia in rats with streptozocin-induced diabetic neuropathy. *Pain* 2009, **145**:184–195.
16. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, Park J, Chen CC, Campbell KP, Shin HS: Attenuated pain responses in mice lacking Cav3.2 T-type channels. *Genes Brain Behav* 2007, **6**:425–431.
17. García-Caballero A, Gadotti VM, Stembkowski P, Weiss N, Souza IA, Hodgkinson V, Bladen C, Chen L, Hamid J, Pizzoccaro A, Deage M, François A, Bourinnet E, Zamponi GW: The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. *Neuron* 2014, **83**:1144–1158.
18. Aggarwal SK: Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. *Clin J Pain* 2013, **29**:162–171.
19. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinnet E, Chemin J: T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. *J Neurosci* 2009, **29**:13106–13114.
20. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Philippe L: Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. *EMBO J* 2001, **20**:7033–7040.
21. Gilmore AJ, Heblinski M, Reynolds A, Kassiou M, Connor M: Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. *Br J Pharmacol* 2012, **165**:1076–1088.
22. Ross HR, Gilmore AJ, Connor M: Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine. *Br J Pharmacol* 2009, **156**:740–750.
23. Gadotti VM, You H, Petrov RR, Berger ND, Diaz P, Zamponi GW: Analgesic effect of a mixed T-type channel inhibitor/CB<sub>2</sub> receptor agonist. *Mol Pain* 2013, **9**:32.
24. You H, Gadotti VM, Petrov RR, Zamponi GW, Diaz P: Functional characterization and analgesic effects of mixed cannabinoid receptor/T-type channel ligands. *Mol Pain* 2011, **8**:89.
25. Yue J, Liu L, Liu Z, Shu B, Zhang Y: Upregulation of T-type Ca<sup>2+</sup> channels in primary sensory neurons in spinal nerve injury. *Spine* 2013, **38**:463–470.
26. Jagodic MM, Pathirathna S, Joksovic PM, Lee W, Nelson MT, Naik AK, Su P, Jevtovic-Todorovic V, Todorovic SM: Upregulation of the T-type calcium current in small rat sensory neurons after chronic constriction injury of the sciatic nerve. *J Neurophysiol* 2008, **99**:3151–3156.
27. Jagodic MM, Pathirathna S, Nelson MT, Mancuso S, Joksovic PM, Rosenberg ER, Bayliss DA, Jevtovic-Todorovic V, Todorovic SM: Cell-specific alteration of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons. *J Neurosci* 2007, **27**:3305–3316.
28. Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer D: Central and peripheral sites of action for CB<sub>2</sub> receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. *Br J Pharmacol* 2011, **162**:428–440.
29. Mackie K: Distribution of cannabinoid receptors in the central and peripheral nervous system. *Handb Exp Pharmacol* 2005, **168**:299–325.
30. Morrisset V, Urban L: Cannabinoid-induced presynaptic inhibition of glutamatergic EPSCs in substantia gelatinosa neurons of the rat spinal cord. *J Neurophysiol* 2001, **86**:40–48.
31. Agarwal N, Pacher P, Tegeder F, Amaya F, Constantin CE, Brenner GJ, Rubino T, Michalski CW, Marsicano G, Monory K, Mackie K, Marian C, Batkai S, Paralaro D, Fischer MJ, Reeh P, Kunos G, Kress M, Lutz B, Woolf CJ, Kuner R: Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. *Nat Neurosci* 2007, **10**:870–879.
32. Long JZ, Li W, Booker L, Burston JJ, Kinsey SG, Schlosburg JE, Pavón FJ, Serrano AM, Selley DE, Parsons LH, Lichtman AH, Cravatt BF: Selective blockage of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioural effects. *Nat Chem Biol* 2009, **5**:37–44.
33. Savinainen JR, Jävinen T, Laine K, Laitinen JT: Despite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB<sub>1</sub> receptor-dependent G-protein activation in rat cerebellar membranes. *Br J Pharmacol* 2001, **134**:664–672.
34. Naidu PS, Kinsey SG, Guo TL, Cravatt BF, Lichtman AH: Regulation of inflammatory pain by inhibition of fatty acid amide hydrolase. *J Pharmacol Exp Ther* 2010, **334**:182–190.
35. Martins DF, Mazzardo-Martins L, Cidral-Filho FJ, Gadotti VM, Santos AR: Peripheral and spinal activation of cannabinoid receptors by joint mobilization alleviates postoperative pain in mice. *Neuroscience* 2013, **255**:110–121.
36. Malmberg AB, Basbaum AI: Partial sciatic nerve injury in the mouse as a model of neuropathic pain: behavioural and neuroanatomical correlates. *Pain* 1998, **76**:215–222.

doi:10.1186/1744-8069-10-77

Cite this article as: Berger et al.: NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB<sub>2</sub> receptors. *Molecular Pain* 2014 **10**:77.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
www.biomedcentral.com/submit

